Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 223

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 223
---
quired by Thermo Fisher Scientific,
Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang
was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and Ph.D. in Biology from The Johns Hopkins
University. We believe that Dr. Hwang is well-qualified to serve as a director of our company based on his familiarity with Profusa’s
business, his experience in the life science industry, and his educational background.

Fred Knechtel — Fred
Knechtel has served as our Chief Financial Officer and director since July 2025. From August 2022 to August 2023, Mr. Knechtel
served as chief financial officer of DiamiR Biosciences. From January 2020 to January 2021, Mr. Knechtel served as chief
financial officer of Interpace Biosciences, Inc. From June 2018 to December 2018, Mr. Knechtel served as chief financial
officer of GENEWIZ, Inc. From November 2014 to November 2017, Mr. Knechtel served as group chief financial officer of Sims
Metal Management. From November 2009 to October 2014, Mr. Knechtel served as chief financial officer of Remy International,
Inc. Mr. Knechtel received a Bachelor of Engineering from Stony Brook University and a M.B.A in Finance from Hofstra University.
We believe that Mr. Knechtel is well-qualified to serve as a director of our company based on Mr. Knechtel’s experience
holding high level executive positions in the life sciences industry, and his financial and accounting experience.

Rajesh Asarpota — Mr. Asarpota
is currently the chief financial officer at Augmedics, a company that has pioneered cutting-edge augmented reality technologies to improve
surgical outcomes for spine surgery. Prior to Augmedics, from September 2020 to October 2021, he served at ApiJect as executive
vice president, chief financial officer and head of technology. ApiJect is a medical technology company that seeks to revolutionize how
medicines and vaccines are filled, finished and delivered. Prior to ApiJect, from August 2017 to September 2020, Asarpota served
as executive vice president and chief financial officer with NuVasive